JP7881538B2 - 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法 - Google Patents

治療薬のネコにおける半減期を増加させるための組成物及びその使用方法

Info

Publication number
JP7881538B2
JP7881538B2 JP2023501003A JP2023501003A JP7881538B2 JP 7881538 B2 JP7881538 B2 JP 7881538B2 JP 2023501003 A JP2023501003 A JP 2023501003A JP 2023501003 A JP2023501003 A JP 2023501003A JP 7881538 B2 JP7881538 B2 JP 7881538B2
Authority
JP
Japan
Prior art keywords
feline
amino acid
polypeptide
wild
axis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534636A (ja
JP2023534636A5 (enExample
Inventor
ブロンディク、ウィリアム
シュヴァリエ、ブレット
ホーン、ユルゲン
ナタラジャン、マドゥズーダン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invetx Inc
Original Assignee
Invetx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invetx Inc filed Critical Invetx Inc
Publication of JP2023534636A publication Critical patent/JP2023534636A/ja
Publication of JP2023534636A5 publication Critical patent/JP2023534636A5/ja
Priority to JP2026064109A priority Critical patent/JP2026126235A/ja
Application granted granted Critical
Publication of JP7881538B2 publication Critical patent/JP7881538B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023501003A 2020-07-10 2021-06-23 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法 Active JP7881538B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026064109A JP2026126235A (ja) 2020-07-10 2026-04-09 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063050535P 2020-07-10 2020-07-10
US63/050,535 2020-07-10
US202163143720P 2021-01-29 2021-01-29
US63/143,720 2021-01-29
PCT/US2021/038714 WO2022010652A1 (en) 2020-07-10 2021-06-23 Compositions for increasing half-life of a therapeutic agent in felines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026064109A Division JP2026126235A (ja) 2020-07-10 2026-04-09 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2023534636A JP2023534636A (ja) 2023-08-10
JP2023534636A5 JP2023534636A5 (enExample) 2024-07-01
JP7881538B2 true JP7881538B2 (ja) 2026-06-29

Family

ID=77043030

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023501003A Active JP7881538B2 (ja) 2020-07-10 2021-06-23 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法
JP2026064109A Pending JP2026126235A (ja) 2020-07-10 2026-04-09 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026064109A Pending JP2026126235A (ja) 2020-07-10 2026-04-09 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法

Country Status (11)

Country Link
US (4) US11498953B2 (enExample)
EP (1) EP4178977A1 (enExample)
JP (2) JP7881538B2 (enExample)
KR (1) KR20230038522A (enExample)
CN (2) CN116096741B (enExample)
AU (1) AU2021306179A1 (enExample)
BR (1) BR112022027028A2 (enExample)
CA (1) CA3188448A1 (enExample)
MX (1) MX2023000500A (enExample)
TW (1) TW202216749A (enExample)
WO (1) WO2022010652A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
EP4166574A4 (en) * 2020-06-10 2025-01-15 Bica Therapeutics Inc. FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
EP4255933A4 (en) * 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
US20240400708A1 (en) * 2020-12-18 2024-12-05 Zoetis Services Llc Mutations in feline antibody constant regions
AU2023415535A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
IL322604A (en) * 2023-02-08 2025-10-01 Levicept Ltd Fusion protein
EP4669757A1 (en) 2024-03-21 2025-12-31 Akston Biosciences Corporation PD-L1 ANALOGUE FUSION PROTEINS FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY AND METHODS OF USE
CN121779581B (zh) * 2026-03-09 2026-06-16 华中农业大学 长效猫粒细胞巨噬细胞集落刺激因子重组蛋白、及其cho细胞表达方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510466A (ja) 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド エフェクター機能が変更しているポリペプチド変異体
WO2020082048A1 (en) 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
WO2020116560A1 (ja) 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
CA2169298A1 (en) 1993-09-10 1995-03-16 Martin Chalfie Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
BRPI0514068B8 (pt) * 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2010110838A2 (en) 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
AU2012252152B2 (en) 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2016044676A2 (en) * 2014-09-18 2016-03-24 AskGene Pharma, Inc. Novel feline erythropoietin receptor agonists
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3481413A4 (en) 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
JP7449234B2 (ja) 2018-03-16 2024-03-13 ゾエティス・サービシーズ・エルエルシー 獣医学使用のためのインターロイキン３１モノクローナル抗体
JP2022500037A (ja) 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
WO2020139984A1 (en) 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN115135669B (zh) 2020-02-19 2026-05-19 硕腾服务有限责任公司 修饰的Fc区
IL297287A (en) 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
EP4136109A1 (en) 2020-04-17 2023-02-22 Zoetis Services LLC Feline antibody variants
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
KR20230104157A (ko) 2020-10-07 2023-07-07 조에티스 서비시즈 엘엘씨 항-ngf 항체 및 그의 사용 방법
TW202607038A (zh) 2020-10-19 2026-02-16 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
US20240400708A1 (en) 2020-12-18 2024-12-05 Zoetis Services Llc Mutations in feline antibody constant regions
US20250011410A1 (en) 2021-11-23 2025-01-09 Invetx, Inc. Anti-ngf antibodies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510466A (ja) 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド エフェクター機能が変更しているポリペプチド変異体
WO2020082048A1 (en) 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
WO2020116560A1 (ja) 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体

Also Published As

Publication number Publication date
US20230090405A1 (en) 2023-03-23
JP2023534636A (ja) 2023-08-10
MX2023000500A (es) 2023-04-12
CN116096741A (zh) 2023-05-09
CN116096741B (zh) 2024-10-18
US11739135B2 (en) 2023-08-29
WO2022010652A1 (en) 2022-01-13
KR20230038522A (ko) 2023-03-20
BR112022027028A2 (pt) 2023-03-07
US20220259282A1 (en) 2022-08-18
US20220009994A1 (en) 2022-01-13
US12344650B2 (en) 2025-07-01
AU2021306179A1 (en) 2023-03-02
CA3188448A1 (en) 2022-01-13
CN119899259A (zh) 2025-04-29
US20250304650A1 (en) 2025-10-02
US11498953B2 (en) 2022-11-15
JP2026126235A (ja) 2026-08-04
EP4178977A1 (en) 2023-05-17
TW202216749A (zh) 2022-05-01

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260617

R150 Certificate of patent or registration of utility model

Ref document number: 7881538

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150